SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5160-5163. Prepublished online as a Blood First Edition Paper on March 5, 2007; DOI 10.1182/blood-2006-12-063594. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-12-063594v1 109/12/5160    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Neelapu, S. S. Articles by Kwak, L. W. Search for Related Content PubMed PubMed Citation Articles by Neelapu, S. S. Articles by Kwak, L. W. Related Collections Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma Sattva S. Neelapu1, Barry L. Gause2, Linda Harvey3, Seung-Tae Lee1, Andrea Robin Frye2, Jessie Horton2, Richard J. Robb4, Mircea C. Popescu4, and Larry W. Kwak1 1 Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX; 2 Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 3 SAIC, National Cancer Institute (NCI), Frederick, MD; 4 XEME Biopharma, Inc., Plainsboro, NJ Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. The time-consuming process required to generate patient-specific vaccines is a major limitation, however. Here we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease, is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. S. Neelapu and L. W. Kwak Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies Hematology, January 1, 2007; 2007(1): 243 - 249. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020